Dose Finding Study Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects
The purpose of this study is to characterize the safety and tolerability profile of escalating dose levels of ENV8058 (TAK-058) solution when administered as a single oral dose in healthy adults.
The drug being tested in this study is called ENV8058 (also known as TAK-058). ENV8058 is
being tested to find a safe and well-tolerated dose and to assess how ENV8058 moves
throughout the body. This study will look at side effects and lab results in people who took
ENV8058. This study was designed as a randomized, sequential-panel, single rising dose
study.
The study population will consist of 6 Cohorts with 8 participants in each Cohort; with 6
participants randomized to receive a single dose of ENV8058, and 2 participants to receive
placebo. Participants in each Cohort will receive a single dose of study drug after a
10-hour fast. The starting dose is 15 mg followed by administrations of 30, 45, 15, 75 and
150 mg.
- ENV8058 (Tak-058): 5, 15, 30, 45, 75 or 150 mg oral solution
- Placebo (dummy inactive) - this oral solution looks like the study drug but has no
active ingredient
This single-centre trial will be conducted in the United States. The overall time to
participate in this study is up to 14 days. Participants will make 2 visits to the clinic,
including one 5-day period of confinement to the clinic. All participants will be contacted
by telephone 14 days after last dose of study drug for a follow-up assessment.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04730609 -
Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery
|
Phase 4 | |
| Completed |
NCT02123953 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT02141698 -
Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects
|
Phase 1 | |
| Completed |
NCT02706834 -
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02334982 -
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT03595189 -
Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.
|
Phase 1 |